Patent Document

CROSS REFERENCE TO RELATED APPLICATION 
     This application is a divisional of copending application Ser. No. 187,920, filed Sept. 17, 1980, now issued as U.S. Pat. No. 4,338,453. 
    
    
     DESCRIPTION 
     1. Background of the Invention 
     The present invention relates to novel substituted imidazoles. Most particularly, the present invention relates to certain piperazinyl substituted imidazoles. The pharmaceutical use and preparation of these compounds is described in U.S. Pat. No. 4,338,453, which is expressly incorporated herein by reference above. 
     2. Prior Art 
     Various imidazoles are known. These compounds have been described as useful for a wide range of uses. Such known imidazole compounds include 1,2,4,5-tetra-substituted imidazoles useful as antitumor, antiviral, antiinflammatory agent agents, and as protective agents against cerebral anoxia or hypoxia such as are described in British Pat. No. 2,016,011 (abstracted in Derwent Farmdoc CPI No. 68606B/38), French Pat. No. 2,132,632 (abstracted in Derwent Farmdoc CPI No. 10105U-B), U.S. Pat. No. 3,651,080, and Belgian Pat. No. 810,117 (abstracted in Farmdoc CPI No. 41717V/23); 1-substituted imidazoles for use in treating inflammation, hypertension, thrombosis and asthma such as described in Japanese Patent Application 109974 (abstracted in Derwent Farmdoc CPI No. 72897B/40); 1,2-di-substituted-4-haloimidazoles-5-acetic acid derivatives for use as diuretics and hypotensives, as described in U.S. Pat. No. 4,207,324; and 1,4,5-trisubstituted imidazoles useful as antiallergic and hypotensive agents such as described in British Pat. No. 1,134,580. U.S. Pat. No. 3,505,350 discloses certain mercapto imidazole derivatives which are useful as antiinflammatory agents. 
      SUMMARY OF THE INVENTION 
     The present invention particularly provides a compound according to Formula I ##STR1## or a pharmacologically acceptable salt thereof, wherein X 1  is 
     (a) ═CH--; or 
     (b) ═C(CH 3 )--; 
     wherein m is zero, one, 2 or 3; 
     wherein n is zero, one or 2, 
     wherein R 4  is: 
     (a) hydrogen; 
     (b) alkyl of one to three carbon atoms, inclusive; 
     (c) R 54  OCH 2  --, wherein R 54  is defined below; 
     (d) --CH(R 35 )(OH); or 
     (e) --R 35  ; 
     wherein R 5 , R 15 , R 25  and R 35  are the same or different and are 
     (i) 2,3, or 4 pyridinyl, or 
     (ii) phenyl substituted by zero to 2 chloro, fluoro, bromo, alkyl of from one to 3 carbon atoms, or alkoxy of from one to 3 carbon atoms, or 
     (iii) phenyl substituted by one trifluoromethyl and zero to one of the previous phenyl substituents, 
     wherein R 6  is: 
     (a) hydrogen; 
     (b) --OR 54  ; 
     (c) alkanoyloxy of from one to 3 carbon atoms; or 
     (d) alkyl of from one to 3 carbon atoms; with the proviso that when m is zero, R 6  does not contain oxygen; 
     wherein R 7  is 
     (i) hydrogen, 
     (ii) methyl, 
     (iii) phenylmethyl, or 
     (iv) phenylethyl, 
     wherein R 8  is 
     (i) --R 15  ; 
     (ii) --CH 2  R 15 , or 
     (iii) --CHR 15  R 25  ; 
     wherein R 17  is methyl, phenyl, benzyl, or 2-phenylethyl; and wherein R 54  is hydrogen or alkyl of one to 3 carbon atoms; or an enantiomer (when R 4  is --CH(R 35 )OH or when R 6  is not hydrogen) or diastereomer (when R 4  is --CH(R 35 )OH and R 6  is not hydrogen) of such compound. 
    
    
     DESCRIPTION OF THE PREFERRED EMBODIMENTS 
     The present invention particularly provides: 
     1-[2-(5-Methyl-1-phenyl-1H-imidazol-2-yl)ethyl]-4-phenylpiperazine; 
     1-(4-Chlorophenyl)-4-[2-(5-methyl-1-phenyl-1H-imidazol-2-yl)ethyl]piperazine; 
     1-(4-Fluorophenyl)-4-[2-[1-(4-fluorophenyl)-5-methyl-1H-imidazol-2-yl]ethyl]piperazine; 
     1-(4-Chlorophenyl)-4-[2-[1-(4-fluorophenyl)-5-methyl-1H-imidazol-2-yl]ethyl]piperazine; and 
     1-[2-[1-(4-Fluorophenyl)-5-methyl-1H-imidazol-2-kyl]ethyl]-4-phenylpiperazine.

Technology Category: c